Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scotland echoes NICE (UK National Institute for Clinical Excellence) advice on MoM (metal on metal) hips:

This article was originally published in Clinica

Executive Summary

The Health Technology Board for Scotland (HTBS) has approved National Institute for Clinical Excellence (NICE) guidance on the use of metal on metal (MoM) hip resurfacing by NHSScotland. In June 2002, NICE recommended that MoM resurfacing be considered for people with advanced hip disease who would otherwise receive a conventional total hip replacement (THR) and are likely to live longer than the device is likely to last (see Clinica No 1013, p 5). Scotland performed 3,304 THRs in 2001. Around 320 people annually are likely to be eligible for MoM resurfaced hips in Scotland, said HTBS medical director Dr Harpreet Kohli. Around 4,500 patients annually are expected to be eligible in England and Wales.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel